| Biomarker ID | 1347 |
| PMID | 24565955 |
| Year | 2014 |
| Biomarker | Bone Alkaline Phosphatase [BAP] |
| Biomarker Basis | Concentration Based (u/L) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 1.23 (95% CI: 1.14-1.32) |
| Effect on Pathways | NA |
| Experiment | Overall Survival Vs No Survival |
| Type of Biomarker | Prognostic |
| Cohort | 778 patients were randomly divided into two groups: Docetaxel/ atrasentan (n=382) and Docetaxel/placebo (n=396) |
| Senstivity | NA |
| Specificity | NA |
| AUC | Atrasentan Arm: 0.68; Placebo Arm: 0.66 |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | ELISA |
| Clinical | Yes |
| Remarks | Estimates for the difference between arms (atrasentan – placebo) in the mean change in log2 bone marker concentrations (from baseline to week9), adjusted for bisphosphonate usage. |
| Clinical Trial Number | NCT00134056 |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |